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Abstract
Background: Human Papillomavirus type 16 (HPV16) causes over half of all cervical cancer and some HPV16 variants are
more oncogenic than others. The genetic basis for the extraordinary oncogenic properties of HPV16 compared to other
HPVs is unknown. In addition, we neither know which nucleotides vary across and within HPV types and lineages, nor which
of the single nucleotide polymorphisms (SNPs) determine oncogenicity.
Methods: A reference set of 62 HPV16 complete genome sequences was established and used to examine patterns of
evolutionary relatedness amongst variants using a pairwise identity heatmap and HPV16 phylogeny. A BLAST-based
algorithm was developed to impute complete genome data from partial sequence information using the reference
database. To interrogate the oncogenic risk of determined and imputed HPV16 SNPs, odds-ratios for each SNP were
calculated in a case-control viral genome-wide association study (VWAS) using biopsy confirmed high-grade cervix
neoplasia and self-limited HPV16 infections from Guanacaste, Costa Rica.
Results: HPV16 variants display evolutionarily stable lineages that contain conserved diagnostic SNPs. The imputation
algorithm indicated that an average of 97.561.03% of SNPs could be accurately imputed. The VWAS revealed specific
HPV16 viral SNPs associated with variant lineages and elevated odds ratios; however, individual causal SNPs could not be
distinguished with certainty due to the nature of HPV evolution.
Conclusions: Conserved and lineage-specific SNPs can be imputed with a high degree of accuracy from limited viral
polymorphic data due to the lack of recombination and the stochastic mechanism of variation accumulation in the HPV
genome. However, to determine the role of novel variants or non-lineage-specific SNPs by VWAS will require direct
sequence analysis. The investigation of patterns of genetic variation and the identification of diagnostic SNPs for lineages of
HPV16 variants provides a valuable resource for future studies of HPV16 pathogenicity.
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Introduction
Human papillomaviruses (HPVs) are a highly prevalent,
globally distributed group of DNA viruses infecting cutaneous
and mucosal epithelia throughout the human body [1,2]. HPV
type 16 (HPV16) is the most potent carcinogen and the most
studied of the HPVs [3,4]. Persistent infection with high-risk HPV
is responsible for over 90% of invasive cervical cancers worldwide;
HPV16 accounts for approximately two thirds of the cervical
cancers [3,4] and up to 90% of HPV-associated extra-cervical
tumors [5]. HPVs contain a 7.9-kb circular double-stranded DNA
genome that consists of four parts: an early region, a late region,
an upstream regulatory region (URR) and a small, highly variable,
non-coding region (NCR) between E5 and L2 (figure 1). All known
HPV types, of which there are over 150, have nearly identical gene
content and organization. An individual HPV type is defined
based on the cloned genome being at least 10% different in the L1
open reading frame nucleotide sequence from all other charac-
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sequence diversity [1,6]. Collectively, HPVs show a range of tissue
tropisms and associated pathologic manifestations such as skin
warts, respiratory papillomatosis, condyloma acuminata and
cervix cancer, all associated with different evolutionarily related
HPV genomes [1,6].
Genetically, papillomaviruses (PVs) evolve slowly, with a
mutation rate of approximately 260.5610
28 per nucleotide per
year [7]. They are predominantly host- and tissue-specific, with
HPV16 displaying Darwinian selection at a limited set of codon
sites across the whole genome [8]. In addition, PVs show little, if
any, definitive recombination throughout their evolutionary
history. Consequently for HPV genetics, nucleotide polymor-
phisms have occurred through random mutation and subsequently
become fixed within a small number of viral lineages, within each
type, over evolutionary time [8,9,10]; for HPV16, variant lineages
are currently named according to population groups in which they
are most prevalent (see [1,11,12] for definitions). Current
knowledge of HPV and cervix oncogenesis is primarily based on
the association of categorically classified high-risk (HR) HPV types
[3,4,13] and in some cases variant lineages of HPV types (e.g.,
HPV16 non-European variant lineages) [10]. However, to
advance understanding of the genetic basis of HPV-associated
carcinogenesis, it is anticipated that complete sequencing of many
hundreds to thousands of HPV genomes from large population-
based and case-control studies of cervix neoplasia and cancer will
be required [14].
Genotype imputation relies on a high correlation between
genetic variants at sites across the genome of an organism (for
review see [15]). In genome-wide association studies (GWAS),
imputation can improve the coverage of genotyping arrays
[15,16,17], which only measure a small proportion of genetic
variation in a study sample. Typically, a subset of single nucleotide
polymorphisms (SNPs) from individuals in a study population is
assayed for association with a particular disease or phenotypic
trait. It is possible to use partial genotype data together with
information about shared stretches of DNA (e.g., linkage
disequilibrium (LD) data available from the HapMap project) to
detect associations between unmeasured SNPs and a given disease
or phenotype [15]. In contrast, lineage fixation of DNA
polymorphisms within the HPV genome leads to the possibility
of imputing missing genomic sequences from short regions using
the growing assembly of diverse complete HPV16 genome
sequences [8].
Although the extraordinarily high association (odds ratio .300)
between HPV16 and cervical cancer [18] is strictly related to the
DNA content of the HPV16 genome, the specific underlying
genetic basis of the association is unknown. To address this, we
performed two analyses. The first assessed HPV16 phylogeny and
patterns of genetic variation from a reference set of complete
genome HPV16 sequences covering all known lineages. In
studying these, we identified diagnostic SNPs across the genome
for all major lineages of HPV16. The second investigated the use
of imputed SNPs in a viral genome-wide association study (VWAS)
from a set of HPV16 sequenced fragments from the URR/E6
region. In order to obtain complete genomes from the partial
genomic data, we developed and tested an automated method to
impute missing nucleotides using a reference database, stand-alone
BLAST+ [19] and a custom BLAST output parser written in
Mathematica 7.0 (Wolfram Research, Inc., Mathematica, Version
7.0, Champaign, IL, 2008). This methodology was found more
suitable for HPV than other currently existing imputation software
(e.g., fastPHASE [20] and IMPUTE [21]). All SNP sites identified,
including diagnostic SNPs, were then tested for association with
disease outcome (i.e., histologically confirmed cervical intraepi-
thelial neoplasia 3 and cancer (CIN3+)). The analyses presented
here focused on the HPV16 positive patients in the HPV Natural
History Study in Guanacaste, Costa Rica [10], indicating the
feasibility of future large scale VWASs in HPV-associated cancer.
This report reveals a new appreciation of HPV16 sublineages as
risk determinants.
Results
Inter-sequence identity and phylogeny
A global alignment (available from authors upon request) of
HPV16 complete genomes was performed to examine patterns of
nucleotide variation. The panel consisted of 62 complete genome
sequences (Table S1) containing isolates representing the majority
of known HPV16 variant lineages (for NCBI accession numbers
see Supplemental Table S1). The resulting alignment was 7916 bp
and introduced a maximum of 10 insertions/deletions (indels)
across all sequences. All indels were within the highly variable
non-coding region between E5 and L2 (NCR, positions 4102–
4236, see Fig. 1) of the HPV16 genome. A pairwise comparison
between all sequences identified a total of 540 single nucleotide
polymorphisms (SNPs) with any pair of sequences having a
maximum of 180 (2.3% of genome) differences.
Prior phylogenetic analyses of HPV16 variants [8,22,23,24]
identified 4 major intratypic variant lineages: European (E), Asian-
American (AA), African-1 (Af-1) and African-2 (Af-2). Figure 2
Figure 1. A schematic representation of the HPV16 genome.
The 7,908 bp circular, double-stranded DNA genome of the HPV16
reference sequence is illustrated. Genes expressed early in the viral life
cycle (early genes) are drawn with solid black lines and their names
prefixed by an ‘‘E’’. Genes expressed late in the viral life cycle (late
genes) that encode the structural capsid proteins, are indicated by blue
lines and have names prefixed by an ‘‘L’’. The upstream regulatory
region (URR) and a second non-coding region (NCR) are drawn in gray.
The viral genome and positions within the DNA sequence are displayed
by the helix and numbers, respectively.
doi:10.1371/journal.pone.0021375.g001
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heatmap of the pairwise identities between all HPV16 complete-
genome sequences in the reference panel (Fig. 2). In addition to
the differences between the major variants, there appears to be
sublineage structure; a feature notably well developed within the
AA lineage. The tree demonstrates excellent support (i.e., all
partitions have posterior probability of 1.0) for the placement of all
named lineages and sublineages (Chen et al., manuscript in
preparation); E, Non-E, European prototype (E(p)), European
Asian (E(As)), Af-1, Af-2, AA, North American (NA1), Asian-
American 1 and 2 (AA1 and AA2). Where, by ‘‘sublineages’’ we
refer to groups of sequences with 0.5% –1.0% differences between
their genomes [25]. Sublineages appear as distinct blocks of similar
color in Figure 2. Taken together, these analyses suggest the
presence of evolutionarily fixed sublineages at a deeper taxonomic
level than the 4 commonly recognized variant clades (i.e., E, AA,
Af-1 and Af-2) [8].
Analysis of genetic variation
To evaluate the ability to use sequence information from
limited, specific regions of the HPV16 genome for imputation, we
had to determine the correlation of SNPs between regions. Due to
the non-recombinant nature of HPV, diagnostic (i.e., lineage-
specific) SNPs could be identified and plotted against position in
the genome for each separate phylogenetic lineage (Fig. 3). Of
note, non-lineage-specific SNPs appear in some genomes and not
others with a pattern independent of lineage (e.g., T350G appears
in some E and all characterized AA genomes). The analysis
showed that any given fragment of the genome $500 bp in size
would contain SNPs enabling discrimination of E from Non-E (see
Fig. 3, rows 2 and 5). At deeper nodes within the phylogenetic tree,
some lineages showed diagnostic SNPs that are only present within
a particular region of the genome. For example, the Af-1 lineage
(Fig. 3, row 4) has no diagnostic SNPs in the first 3900 bp of the
genome, thus most of this region could not be used to assign a
lineage of Af-1(see Fig. 3). This indicates that specific regions of the
genome differ in their capacities for lineage assignment.
The L1, E6 and/or the URR regions of the HPV16 genome are
frequently utilized for variant studies. Typically, epidemiological
studies assign HPV16 lineage based upon the nucleotide sequence
of one or more of these regions [26,27]. The SNP distribution
analysis (Fig. 3) revealed that the URR region contained sufficient
diagnostic SNPs to discriminate between all distinct sublineages:
E(p), EAs, Af-1, Af-2, NA1, AA1 and AA2. Thus, SNPs that occur
Figure 2. HPV16 phylogeny and heatmap of HPV16 isolates in the reference panel. All 62 nucleotide sequences in the HPV16 complete-
genome reference panel were aligned and compared to one another. Sequence identity between every pair was measured and represented as a
heatmap, scaled such that the minimum inter-sequence identity (97.6%) is displayed as red and the maximum inter-sequence identity (100%) as blue.
A Bayesian phylogenetic tree is shown alongside the heatmap to illustrate how the inter-sequence identities relates to the phylogenetic topology.
Major lineages (highlighted in gray) and sublineages are labeled and all have 100% bootstrap support.
doi:10.1371/journal.pone.0021375.g002
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that occur across the rest of the genome. This observation
indicates that imputation based on matching partial regions by
sequence identity would assign a sequence from the correct
sublineage when the URR region was known. In addition to the
URR, the E2/E4 overlap region was found to provide
discriminatory power, through combinatorial sets of SNPs,
between all identified HPV16 sublineages despite containing no
unique diagnostic SNPs for the AA and Af-1 lineages (Fig. 3).
The L1 ORF was found to allow discrimination between all but
the E(As)/E(p) sublineages. By contrast, the E6 ORF was able to
resolve the two European sublineages (E(p) vs. E(As)), and the
African sublineages (Af-1 vs. Af-2), but unable to distinguish the
Asian-American sublineages (NA1 vs. AA1 vs. AA2). The E6 and
L1 ORFs, individually, provide limited information on viral
lineage. In summary, the URR and E2/E4 overlap region contain
diagnostic SNPs that can be genotyped to determine HPV16 viral
lineage. All diagnostic SNPs (plotted in Figure 3) are listed in
Table S2.
Imputation
The first stage of the imputation procedure, search of the
partial-genome query sequences (i.e., previously determined
URR/E6 fragments [10]) against the database of complete
HPV16 genomes by BLAST, identified several best matches for
many of the query sequences amongst the complete-genome
library (mean number of equally high scoring BLAST hits per
partial sequence =6.862.7 (s.d.)). This indicated that sequence
information from the genome fragments was not always sufficient
to uniquely determine the exact genotype from amongst the group
of HPV16 reference sequences. To address this issue, we randomly
sampled from the pool of equally well matching complete genome
sequences 100 times to produce multiple imputations that could be
used in further analyses (see Materials and Methods).
Characterizing imputation error rate
The accuracy of sequence imputation was estimated using three
different methods: imputation using the URR sequence (833
nucleotides) from each of the 62 complete genomes in the
reference database with and without removal of the test genome;
and, complete-genome sequencing of 8 previously unsequenced,
randomly selected samples from amongst the imputed study
samples (for NCBI accession numbers see Supplemental Table
S1). Imputation with removal of the test genome was used to
estimate the error introduced by imputation when the true
sequence was not present in the reference panel. The mean
estimated proportion of correctly imputed SNPs in this case was
527.562.4 out of 540 (97.6860.45%) SNPs. Testing imputation
without removal of the true genome sequence estimated the
possible error introduced when the true sequence was present in
the reference panel. Error in this scenario is introduced when
matches are identical in the test region (e.g., the URR), but
different across the rest of the genome. The mean estimated
proportion of correctly imputed SNPs under these conditions was
537.361.9 out of 540 (99.5160.35%) SNPs. Complete-genome
sequencing was performed on a randomly selected subset of 8
samples containing HPV16 genomes not previously sequenced.
This method showed that a mean of 527.065.5 out of 540
(97.5261.03%) of known SNPs in the sample population were
imputed correctly.
Case-control HPV16 SNP association analysis
To evaluate the association of all known SNPs amongst HPV16
variants with an outcome of CIN3+ compared to the HPV16
infections that resolved, a plot of odds ratios against SNP position
in the genome was performed for the imputed data sets (Fig. 4).
The plot produced a pattern of stratified odds ratios, rather than
demonstrating a small number of high odds ratio SNPs. The
highest ‘‘stratum’’ was occupied, upon inspection, by the
diagnostic SNPs of a distinct sublineage (AA1), suggesting a
higher risk for CIN3+ (see top red box in Fig. 4). Overall odds
ratio calculations showed an increased association of the AA
lineage with CIN3+, OR =1.73 (p=0.07, 95% C.I. 0.95–3.18).
Analyzed individually, the AA1 sublineage was found to have an
odds ratio of 2.24 (p=0.16, 95% C.I. 0.74–6.81) and the AA2
sublineage, an odds ratio of 1.46 (p=0.30, 95% C.I. 0.71–2.97),
Figure 3. Lineage-specific single nucleotide polymorphisms (SNPs) in HPV16 variants and their position in the genome. Lineage-
specific SNPs were determined from an alignment of the 62 complete-genome nucleotide sequences by selecting the nucleotides that occurred only
in members of a given lineage. The value of each SNP is color-coded as shown at the top right of the figure. The SNPs are plotted by position in the
HPV16 genome on the x-axis and aligned according to lineage in the phylogenetic tree on the y-axis. SNPs for a given lineage are cumulative as the
tree is traversed from deepest node out to branches. Thus, for example, HPV16 genomes of Af-2 lineage (row 6) contain all SNPs shown on the Non-E
(row 5), AA/NA1/Af-2 (row 7) and Af-2 (row 6) lines. Regions of the genome are displayed below the x-axis for reference.
doi:10.1371/journal.pone.0021375.g003
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shown in Fig. 4 (see both red boxes). Further analysis revealed that
all lineages occupied their own strata (i.e., lineage-specific SNPs
for a given lineage all had equal odds ratios), consistent with the
lineage fixation of SNPs in the HPV genome [8]. Non-lineage-
specific SNPs yielded a range of odds ratios between 0 and 2.35
(that of the AA1 lineage). Although none of the SNPs’ odds ratios
in Figure 4 reached statistical significance, this analysis did provide
novel insights not anticipated prior to the analysis. In particular,
the possibility that a specific sublineage (AA1) may be driving the
increased odds ratio of pooled Non-European variants was a
surprise and has broad implications.
Discussion
The association of HPV and cervix cancer has always been
based on the detection of the HPV genome, since standard
virologic methods proved insensitive [28]. The association of HPV
genomes with cervix cancer was first established prior to the
development of PCR when only crude assays were available and
there was limited ability to distinguish individual HPV types [29].
With the development and improvement of HPV assays, it became
well recognized throughout the world that association with cervix
cancer risk was based on the DNA sequence of the HPV genomes,
with the genome of HPV16 having an extraordinary association
with cervix cancer [18]. Other evolutionarily related HPV
genomes, predominantly of the alpha-9 (HPV16-related) and
alpha-7 (HPV18-related) species groups, were also shown to be
associated with cervix cancer, but less so than HPV16.
Nevertheless, the underlying nucleotide changes responsible for
the association with cancer and more specifically, the huge risk
associated with HPV16, have gone largely unsolved. Further
developments in DNA sequencing technology allowed a finer
resolution of HPV types into variant lineages, and application of
sequencing short regions of the HPV genome provided compelling
evidence that variants of HPV16 of the non-European lineage had
a stronger association with high-grade cervix neoplasia and cancer
than the European lineage [10,30,31]. This report is a step
forward in understanding the genetic basis of HPV carcinogenicity
at the nucleotide level. We assessed sequence imputation from a
large number of complete genome sequences using knowledge
about the evolution of HPV16 genomes [8] and demonstrate that
lineage fixation is so strong that diagnostic SNPs for evolutionarily
stable variant sublineages can be found and are distributed across
the genome. We observed a subgroup of an HPV16 AA variant
lineage with a possibly elevated risk for CIN3+ within this host
population. This latter observation suggests that future work might
be able to stratify a virus carrier’s risk of precancer or cancer by
different lineages, sublineages and possibly even smaller evolved
groupings.
At the nucleotide level, we show that the fixation of most SNPs
within lineages allows imputation of the conserved lineage specific
SNPs with high accuracy; however, the majority of imputed SNPs
do not provide new information on risk assessment, since they are
highly correlated. Causal SNPs that happen to be lineage-specific
cannot be distinguished from non-causal lineage-specific SNPs,
based on odds ratio. This is due to the high lineage fixation
(equivalent to linkage disequilibrium in recombining genomes) in
HPV16 and means that, as performed here, phylogenetic
information must be taken into account when analyzing SNPs
with elevated odds ratios in HPV. SNPs within high LD (non-
recombining) regions of the human and other diploid genomes will
have similar properties. In addition, the set of non-lineage-specific
SNPs, those that are not correlated with the set of measured SNPs,
Figure 4. HPV16 viral genome-wide association study (VWAS). Odds ratios for an outcome of CIN3+ vs. resolved HPV16 infections were
calculated for every SNP that occurred .10 times in the imputed and determined nucleotide sequences for 412 HPV16 positive samples from the
Guanacaste, Costa Rica cohort [10]. Odds ratios for each SNP are plotted against their position in the genome. Some stratification of SNPs by odds
ratio is evident. By mapping the bands of SNPs back to the lineage-specific SNP plot, it was possible to determine that the band with the highest
odds ratio was composed of SNPs from the AA1 sublineage. For comparison, red boxes indicate the bands containing AA1- and AA2-specific SNPs.
Due to statistical power limitations in this study, none of the SNPs attained viral genome-wide significance. Despite this, the plot suggests differences
in disease association between sublineages.
doi:10.1371/journal.pone.0021375.g004
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and pathogenesis can be assessed.
The analysis of genetic relatedness (Fig. 2) between the complete
genomes of a large set of HPV16 isolates, sampled for maximum
diversity from around the world, demonstrated the presence of
distinct and evolutionarily stable sublineages. Analysis of lineage
defining SNPs in the HPV16 genome revealed that for many
nodes on the phylogenetic tree, diagnostic SNPs were distributed
across the entire genome, in contrast to genomes that undergo
recombination with SNPs typically being correlated by distance
[32]. Most publicly available imputation software (e.g., fastPHASE
[20], IMPUTE [21], PLINK [33], EMINIM [16]) requires
pedigree information or large-scale reference panels of haplotypes
with information on several million SNPs, as well as recombina-
tion and mutation parameters which are pre-defined or extrap-
olated from the data. Hidden Markov Models, upon which this
type of software is based, are suited to imputing where typed
(measured) markers are distributed across the entire genome and
are useful for genomes that undergo recombination. Additionally,
because most genetic studies focus on diploid organisms, few of the
publicly available programs are designed to work with other types
of genomes (e.g., double stranded DNA viral genomes such as
HPV). These software (i.e., fastPHASE and IMPUTE) were
evaluated for use with our data, but it was ultimately determined
that a simple BLAST-based approach would more effectively
leverage the properties of our data and HPV genetics, and simplify
interpretation of results.
Imputation error estimation showed that imputation produced
only a small number of erroneously assigned SNPs per sequence
(,20, corresponding to ,0.25% of the genome and ,3.7% of all
known SNP positions in the reference panel). Simulation of
imputation without removal of the test genome was likely an
overestimate of the accuracy, but was used to account for multiple
closely related matches. Simulation of imputation with removal of
the test genome, by contrast, may have underestimated the mean
accuracy, since a proportion of the query samples came from
lineages over-represented in the reference panel. Errors, under the
former circumstances, occur when multiple sequences in the
reference panel are identical over the region covered by the partial
sequence information but different across the remaining genome.
As the database of complete HPV16 genomes expands to cover
essentially all recurring variations throughout the world, it can be
estimated that imputation accuracy will reach a maximum, close
to but not equal to 100%. There will always be a set of SNPs (n <
20) that are variable within and between lineages (e.g., the E6
variable position T350G) that do not allow absolute imputation,
these HPV16 SNPs will require direct determination to evaluate
their risk for cancer.
We used the genome sequences of 412 HPV16 infected cases
and controls (396 imputed and 16 sequenced) to perform a VWAS
to identify SNPs that confer additional risk for developing high-
grade cervical intraepithelial neoplasia. Although this low-power
‘proof of principle’ analysis found no statistically significant
individual SNPs, we identified intriguing trends at the sublineage
level. In this dataset, there is a higher association with CIN3+ for
Non-E lineages than for E lineages [10]. Figure 4 and the
subsequent categorical odds ratio calculation suggest that the
elevated association of the AA1 sublineage may drive the elevated
risk of the Non-E lineage. Morevoer, the AA1 sublineage is
characterized by the presence of just 11 SNPs. This opens the door
to trying to verify lineage-based risk stratification. It also raises the
question whether or not the effect is population specific. If
confirmed, analysis of these 11 SNPs could narrow down the list of
possible mechanisms that are driving differences in pathogenicity.
Further studies with larger populations will be required to
determine the validity of this putative association and whether
risk can be further stratified to more distal lineages.
Materials and Methods
Epidemiological data
Case and control state was obtained from the large population-
based cohort study (10,049 women) conducted in Guanacaste,
Costa Rica, previously described [34,35]. Of the 10,049
participants, 412 who were positive for HPV16 (HPV testing
methods described in [8,36,37,38]) and designated as either case
(patient developed histologically confirmed cervical intraepithelial
neoplasia 3 or cancer (CIN3+)) or control (patient had HPV16
detected but infection resolved) were selected for use in the viral
genome-wide association study (VWAS) proof of principle analysis.
Costa Rican and National Cancer Institute of the United States
institutional review boards approved all study protocols. All
participants signed an informed consent form. The study was also
approved by the Committee on Clinical Investigation at the Albert
Einstein College of Medicine.
HPV16 DNA sequencing
DNA isolated from exfoliated cervical cell samples was used for
all HPV analyses, including initial HPV detection, typing and
variant sequencing, as previously described [8,10,39,40]. HPV16
genome sequences and the NCBI/GenBank accession numbers
are listed in Table S1 in the supplemental material. There were 16
complete-genome sequences and 396 partial sequences from the
nested case-control study. Of the 412 cases and controls, 115 were
cases (CIN3+) and 297 were controls (HPV16 infections that
spontaneously cleared).
Sequence alignment and phylogenetic analysis
Complete-genome sequences of HPV16 (n=62, Supplemental
Table S1) were aligned using CLUSTAL W [41]. Nucleotide
positions are given relative to the HPV16 reference sequence [42].
A Bayesian tree inferred from the alignment of these 62 sequences
was constructed using the Markov Chain Monte Carlo (MCMC)
algorithm in MrBayes v3.1.2 with 10,000,000 cycles, where the
first 1,000,000 cycles were discarded [43,44]. The computer
program ModelTest v3.7 [45] was used to identify the best
evolutionary model; the identified gamma model was set for
among-site rate variation and allowed substitution rates of aligned
sequences to be different.
Heatmap plot and pairwise identity analysis
Pairwise identity analysis between all 62 complete-genome
sequences was performed in Mathematica 7.0 (Wolfram Research,
Inc., Mathematica, Version 7.0, Champaign, IL, 2008; see
Supplemental Data S1 for code). A ClustalW alignment of all
(n=62) sequences in the reference panel was taken as input; an n6
n matrix of all pairwise identities was then produced. The matrix
was plotted as a heatmap and scaled such that the maximum
observed pairwise identity (100%) was represented by blue and the
minimum (97.6%) was represented by red (Fig. 2).
SNP distribution amongst HPV16 viral lineages
Using Mathematica 7.0 (Wolfram Research, Inc.; see Supple-
mental Data S2 for code), SNPs were identified by comparing all
aligned complete-genome sequences then filtered and grouped
according to the lineages [8] for which they were diagnostic, e.g.,
all SNPs that appeared only in sequences of the E lineage were
considered diagnostic for that lineage (Fig. 3, row 2). Similarly,
Imputation of HPV16 Sequences
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addition to the E(p)-specific SNPs (Fig. 3, row 1). Clades with
HPV16 nucleotide sequences differing by a pairwise value of 1.0%
–0.5% were designated as distinct sublineages (e.g., AA1 and
AA2); differences of $1% were considered variant lineages (e.g.,
E, Af1, Af2, AA). Lineage-specific SNPs were displayed against
position in the genome and color-coded as A (green), C (blue), G
(black), T (red) to indicate the nucleotide polymorphism. The plot
was positioned adjacent to the Bayesian phylogenetic tree.
Location and value of the diagnostic SNPs are listed in
Supplemental Table S2.
Genotype imputation
An imputation algorithm was developed and implemented using
a combination of the stand-alone BLAST+ software tools [19] to
perform sequence matching (see Supplemental Data S2), and
Mathematica 7.0 (Wolfram Research, Inc.) to generate the
imputed sequences from the BLAST output (see Supplemental
Data S2).
The imputation algorithm consisted of a set of the following
actions:
N A BLAST search was performed using 396 partial genome
sequences as queries, against a custom BLAST formatted
database of the 62 complete-genome reference panel. Hits
were constrained to the plus strand only.
N For each partial query sequence, the complete-genome
sequence(s) with the highest BLAST scores were selected. In
cases where the query sequence was the concatenated
sequence of more than one region (i.e., URR and E6),
returning separate hits for each region, the complete-genome
sequence(s) with the highest combined BLAST score(s) were
selected.
N The missing nucleotides of the partial query sequences were
completed using the selected best complete-genome sequence.
N In the case of multiple, equally high scoring BLAST hits for a
single query sequence, random sampling of the best hits was
used by generating a 100 sets of imputed nucleotide sequences.
This was done to allow calculation of unbiased confidence
intervals for the subsequent odds ratio analysis. Random
sampling was performed using the built-in random choice
function in Mathematica 7.0 under default options (without
replacement sampling based on the ExtendedCA pseudo-
random number generator, described in the Mathematica 7.0
accompanying documentation).
Error characterization
To estimate the precision of imputation with the set of 62
HPV16 reference genomes and the algorithm used herewith, the
following analyses were performed. Dummy imputations were
conducted using the isolated URR region from each complete-
genome sequence in the HPV16 reference panel as a query
sequence. The reference panel from which the URR sequences
were drawn was used as the BLAST database, under two
conditions: with and without removal of the complete HPV16
sequence from which the query sequence was taken. Imputed
sequences were then compared to the known complete-genome
information at all SNP positions for both methods. For each query
sequence, the mean and standard deviation of the percentage of
correct SNPs across the best matches for each test sequence was
calculated. Averaging the individual means and taking their
standard deviation produced overall estimates for each method.
An empirical estimate of imputation error was performed by
randomly selecting 8 of the 396 samples (<2%) that were subject
to genotype imputation followed by direct sequencing of their
complete genomes. Random selection was performed using the
built-in random sample function in Mathematica 7.0 as described
above. For each of the 8 samples, the true sequence was compared
to 100 imputed sequences. The mean and standard deviation of %
error were calculated for each sequenced sample and the overall
estimate was calculated by taking the average and standard
deviation of the individual means.
Epidemiological analysis
Of the 35 complete-genome sequences determined from the
Guanacaste study and included in the reference database, 16 were
also either cases or controls and were combined with the 396
imputed sequences in the epidemiological analyses. Logistic
regression was performed on the SNP positions using all imputed
sequences and complete genomes in order to compare subjects
with CIN3+ to the HPV16-positive ‘‘control’’ population. Only
SNP positions with adequate sample size (i.e., $10 sequences
possessing a SNP; i.e., variant frequency .2.5%) were analyzed.
In the logistic regression calculations, the reference group at each
position was determined by setting the most prevalent nucleotide
as the referent. Logistic regression was run for each of the 100
imputed datasets, parameter estimates and estimated covariances
were written to separate datasets. The MIANALYZE procedure
was used to combine output data from all analyses. The procedure
reads the parameter estimate and covariance computed in each
individual logistic regression, and creates a summary estimate and
a p-value for each nucleotide position. After Bonferroni correction
for 7916 repeated comparisons of SNPs, p-values were considered
significant if they were #6.32610
-6. Odds ratios and 95%
confidence intervals were calculated by taking exponentials of
the summary estimates. Results were plotted as odds ratios around
1.0, to inspect qualitative trends. All analyses were run using SAS
version 9.1.3 (SAS Institute, Cary, NC).
Supporting Information
Table S1 Designated names, NCBI accession numbers
and lineage assignments for HPV16 isolates.
(PDF)
Table S2 Diagnostic single nucleotide polymorphisms
(SNPs) for HPV16 lineages.
(PDF)
Data S1 Mathematica 7 code for performing imputa-
tion based on BLAST results. A partial sequence of the
HPV16 genome was used to search a database of complete
genomes using BLAST. The results of the BLAST search were
then used to identify the full length genomes that had the highest
score and one complete genome sequence was added to a new file
that was used for further analyses. Code annotations are enclosed
by parentheses and stars, i.e., (*…*). Commands can be pasted
directly into a Mathematica notebook and executed. Test data is
available from the authors by request.
(PDF)
Data S2 Mathematica 7 HPV sequence analysis code.
Mathematica 7 notebook containing code used for performing
sequence analysis on the nucleotide sequences of a reference HPV
complete genome sequence library. Analyses include calculating
pairwise differences and plotting a heatmap of values, as well as
identifying lineage-specific (diagnostic) single nucleotide polymor-
phisms. Code annotations are enclosed by parentheses and stars
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notebook and executed. Test data is available from the authors by
request.
(PDF)
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